Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cvs Health Corp.
Headquarters: Woonsocket, RI, United States of America
Website: http://www.cvshealth.com
Year Founded: 1963
Status: Archived
Industry Sector: RetailTrade
CEO: J. David Joyner
Number Of Employees: 300,000
Enterprise Value: $128,653,180,000
PE Ratio: 17.41
Exchange/Ticker 1: NYSE:CVS
Exchange/Ticker 2: N/A
Latest Market Cap: $85,116,608,512
BioCentury | Feb 6, 2025
Market Access
U.S. biosimilars held back by more than just reimbursement
Iqvia’s latest report cites regulatory requirements, investment costs, and lack of market acceptance and predictability
BioCentury | Jan 18, 2025
Politics, Policy & Law
FTC calls out PBM price gouging of specialty generic drugs
Report says Big 3 PBMs mark up 22% of specialty generics by more than 1,000%
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Aug 30, 2024
Management Tracks
Di Donato to leave Immunocore
Plus: FDA’s Mantha, Fakhouri and Liu lead CDER’s AI Council, and an update from BC Platforms
BioCentury | May 22, 2024
Market Access
What’s behind CVS’s changing adalimumab strategy
Company opens the door to biosimilars on its major formularies while partnering with AbbVie on a co-branded Humira
BioCentury | May 7, 2024
Management Tracks
Seaport rounds out C-suite with new hires
Plus: Germany-based Topas taps new CEO, and updates from Quest, Nimbus and more
BioCentury | Aug 24, 2023
Finance
Aug. 23 Quick Takes: CVS launches biosimilar subsidiary
Plus: Foundery raising $160M for first fund, Apellis shares bounce back and updates from Cellares, Agenus, Pfizer, Astellas and more
BioCentury | Jul 18, 2023
Management Tracks
Ballinger at the helm at Lyndra
Plus: Bryan Stuart to lead Atavistik and updates from EnteroBiotix, PTC, CureVac, CytomX, ProKidney and more
BioCentury | Jun 8, 2022
Politics, Policy & Law
June 7 Quick Takes: Biotech bounce as FTC to scrutinize effect of PBMs on drug prices
Plus DBV meets in peanut-allergic toddlers and updates from Immatics, Edits, Acelyrin and more
BioCentury | Apr 28, 2022
Finance
Biofourmis to grow data platform with General Atlantic-led $300M series D
Medtronic’s Omar Ishrak appointed chairman
Items per page:
1 - 10 of 92